taletrectinib
taletrectinib: 7 clinical trials tracked.
taletrectinib evidence translation
What we can confirm
7 tracked trials
What it means
What to watch
Prepared research question
What is verified about taletrectinib, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence7 indications · 1 study sponsors
Clinical Trial Registry Records (7)
Expanded Access Program of Taletrectinib in Patients With Advanced or Metastatic ROS1-Positive NSCLC
An Open-label, Fixed Sequence Study to Evaluate the Effect of Famotidine on the Pharmacokinetics and Safety of Taletrectinib in Healthy Adult Participant
Primary endpoint: Cmax of Taletrectinib
A Phase 3 Multicenter Double-blind Randomized Study of Taletrectinib Versus Placebo in Patients With ROS1-Fusion Positive Stage IB-IIIA Non-Small Cell Lung Cancer Who Have Undergone Complete Tumor Resection
Primary endpoint: Primary Outcome Measure: To compare the efficacy of taletrectinib with that of placebo, as measured by disease-free survival (DFS) by investigator assessment.
A Phase 3 Multicenter Open-label Study of Taletrectinib Versus a Standard of Care ROS1-Tyrosine Kinase Inhibitor (Crizotinib) in TKI-Naïve Patients With ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (TRUST-III)
Primary endpoint: PFS (Assessed by BIRC)
A Single-Arm, Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of Taletrectinib in Patients With Advanced or Metastatic ROS1 Positive NSCLC and Other Solid Tumors
Primary endpoint: Objective response rate (ORR) by independent radiology review committee (IRC)
A Phase II, Multicenter, Open, Basket Study of AB-106 to Treat the Subjects With Local Progression or Systemic Metastasis Solid Tumors With NTRK Gene Fusion
Primary endpoint: Objective response rate (ORR)
A Multicenter, Open Label, Single Arm Phase 2 Study of AB-106 in the Treatment of Locally Advanced and Metastatic NSCLC
Primary endpoint: Best overall response (BOR) by IRC